241 related articles for article (PubMed ID: 16029787)
1. Comparing measures of acute bowel toxicity in patients with prostate cancer treated with external beam radiation therapy.
Muanza TM; Albert PS; Smith S; Godette D; Crouse NS; Cooley-Zgela T; Sciuto L; Camphausen K; Coleman CN; Ménard C
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1316-21. PubMed ID: 16029787
[TBL] [Abstract][Full Text] [Related]
2. Phase II multicenter randomized study of amifostine for prevention of acute radiation rectal toxicity: topical intrarectal versus subcutaneous application.
Kouloulias VE; Kouvaris JR; Pissakas G; Mallas E; Antypas C; Kokakis JD; Matsopoulos G; Michopoulos S; Mystakidou K; Vlahos LJ
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):486-93. PubMed ID: 15890591
[TBL] [Abstract][Full Text] [Related]
3. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.
Vargas C; Martinez A; Kestin LL; Yan D; Grills I; Brabbins DS; Lockman DM; Liang J; Gustafson GS; Chen PY; Vicini FA; Wong JW
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1297-308. PubMed ID: 16029785
[TBL] [Abstract][Full Text] [Related]
4. Proctitis after external-beam radiotherapy for prostate cancer classified by Vienna Rectoscopy Score and correlated with EORTC/RTOG score for late rectal toxicity: results of a prospective multicenter study of 166 patients.
Goldner G; Tomicek B; Becker G; Geinitz H; Wachter S; Zimmermann F; Wachter-Gerstner N; Reibenwein J; Glocker S; Bamberg M; Feldmann H; Pötzi R; Molls M; Pötter R
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):78-83. PubMed ID: 17189064
[TBL] [Abstract][Full Text] [Related]
5. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
6. Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors. A phase II randomized study using various toxicity scales and rectosigmoidoscopy.
Kouvaris J; Kouloulias V; Malas E; Antypas C; Kokakis J; Michopoulos S; Matsopoulos G; Vlahos L
Strahlenther Onkol; 2003 Mar; 179(3):167-74. PubMed ID: 12627259
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.
King CR; Brooks JD; Gill H; Pawlicki T; Cotrutz C; Presti JC
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1043-8. PubMed ID: 18755555
[TBL] [Abstract][Full Text] [Related]
8. Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: results of a prospective multicenter study.
Vavassori V; Fiorino C; Rancati T; Magli A; Fellin G; Baccolini M; Bianchi C; Cagna E; Mauro FA; Monti AF; Munoz F; Stasi M; Franzone P; Valdagni R
Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1401-10. PubMed ID: 17241754
[TBL] [Abstract][Full Text] [Related]
9. Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in Quality of Life measured by EPIC score.
Simone NL; Ménard C; Soule BP; Albert PS; Guion P; Smith S; Godette D; Crouse NS; Sciuto LC; Cooley-Zgela T; Camphausen K; Coleman CN; Singh AK
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):90-5. PubMed ID: 17855015
[TBL] [Abstract][Full Text] [Related]
10. Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer--a phase II study.
Pinkawa M; Fischedick K; Treusacher P; Asadpour B; Gagel B; Piroth MD; Borchers H; Jakse G; Eble MJ
Radiother Oncol; 2006 Jan; 78(1):41-6. PubMed ID: 16271785
[TBL] [Abstract][Full Text] [Related]
11. Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer.
Karlsdóttir A; Johannessen DC; Muren LP; Wentzel-Larsen T; Dahl O
Radiother Oncol; 2004 Apr; 71(1):43-53. PubMed ID: 15066295
[TBL] [Abstract][Full Text] [Related]
12. Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients.
De Meerleer G; Vakaet L; Meersschout S; Villeirs G; Verbaeys A; Oosterlinck W; De Neve W
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):777-87. PubMed ID: 15465194
[TBL] [Abstract][Full Text] [Related]
13. A phase II randomized study of topical intrarectal administration of amifostine for the prevention of acute radiation-induced rectal toxicity.
Kouloulias VE; Kouvaris JR; Pissakas G; Kokakis JD; Antypas C; Mallas E; Matsopoulos G; Michopoulos S; Vosdoganis SP; Kostakopoulos A; Vlahos LJ
Strahlenther Onkol; 2004 Sep; 180(9):557-62. PubMed ID: 15378186
[TBL] [Abstract][Full Text] [Related]
14. Grading-system-dependent volume effects for late radiation-induced rectal toxicity after curative radiotherapy for prostate cancer.
van der Laan HP; van den Bergh A; Schilstra C; Vlasman R; Meertens H; Langendijk JA
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1138-45. PubMed ID: 17931794
[TBL] [Abstract][Full Text] [Related]
15. Clinical and dosimetric predictors of acute toxicity after a 4-week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial.
Arcangeli S; Strigari L; Soete G; De Meerleer G; Gomellini S; Fonteyne V; Storme G; Arcangeli G
Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):39-45. PubMed ID: 18538488
[TBL] [Abstract][Full Text] [Related]
16. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.
Vargas C; Yan D; Kestin LL; Krauss D; Lockman DM; Brabbins DS; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):141-9. PubMed ID: 16111582
[TBL] [Abstract][Full Text] [Related]
17. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life after adjuvant and salvage postoperative radiotherapy for prostate cancer - a prospective analysis.
Pinkawa M; Fischedick K; Asadpour B; Gagel B; Piroth MD; Holy R; Krenkel B; Eble MJ
Radiother Oncol; 2008 Jul; 88(1):135-9. PubMed ID: 18022263
[TBL] [Abstract][Full Text] [Related]
19. Patient-assessed late toxicity rates and principal component analysis after image-guided radiation therapy for prostate cancer.
Skala M; Rosewall T; Dawson L; Divanbeigi L; Lockwood G; Thomas C; Crook J; Chung P; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):690-8. PubMed ID: 17379434
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer.
Ferrer M; Suárez JF; Guedea F; Fernández P; Macías V; Mariño A; Hervas A; Herruzo I; Ortiz MJ; Villavicencio H; Craven-Bratle J; Garin O; Aguiló F;
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):421-32. PubMed ID: 18325680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
